Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Newborn Screening Saves Lives Reauthorization Act of 2014
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues AHRQ Studies of Orphan DrugsDrug Supply Chain Security H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013 S. 959, Pharmaceutical Quality, Security, and Accountability Act H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013 S. 1417, Newborn Screening Saves Lives Reauthorization Act of 2013 Sequestration of FDA User Fees H.R. 2315, Preserving Access to Orphan Drugs Act of 2013 S. 1128, Preserving Access to Orphan Drugs Act of 2013
Newborn Screening Saves Lives Reauthorization Act of 2014
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
GENZYME CORPORATION via GENZYME CORPORATION
2013 · fourth_quarter · Q4
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues AHRQ Studies of Orphan DrugsDrug Supply Chain Security H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013 S. 959, Pharmaceutical Quality, Security, and Accountability Act H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013 S. 1417, Newborn Screening Saves Lives Reauthorization Act of 2013 Sequestration of FDA User Fees H.R. 2315, Preserving Access to Orphan Drugs Act of 2013 S. 1128, Preserving Access to Orphan Drugs Act of 2013
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013 S. 1871, Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Act of 2013
Source: Senate LDA
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues AHRQ Studies of Orphan DrugsDrug Supply Chain Security: H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013 and S. 959, Pharmaceutical Compounding Quality and Accountability Act H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013
Newborn Screening Saves Lives Reauthorization Act of 2014
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues AHRQ Studies of Orphan DrugsDrug Supply Chain Security: H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013 and S. 959, Pharmaceutical Compounding Quality and Accountability Act H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013 S. 1417, Newborn Screening Saves Lives Reauthorization Act of 2013
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013 S. 1871, Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Act of 2013
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013
Safeguarding America's Pharmaceuticals Act of 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposal S. 959, Pharmaceutical Quality, Security, and Accountability Act H.R. 2186, Verifying Authority and Legality In Drug (VALID) Compounding ActS. 957, Drug Supply Chain Security Act H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013
Safeguarding America's Pharmaceuticals Act of 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposal Prescription Drug Compounding: S. 959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 2186, VALID Compounding Act; The Compounding Clarity ActDrug Supply Chain Security: S. 959, Pharmaceutical Compounding Quality and Accountability Act, and H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013
Safeguarding America's Pharmaceuticals Act of 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues AHRQ Studies of Orphan DrugsDrug Supply Chain Security H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013 S. 959, Pharmaceutical Quality, Security, and Accountability Act H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013 S. 1417, Newborn Screening Saves Lives Reauthorization Act of 2013 Sequestration of FDA User Fees H.R. 2315, Preserving Access to Orphan Drugs Act of 2013 S. 1128, Preserving Access to Orphan Drugs Act of 2013
Safeguarding America's Pharmaceuticals Act of 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues AHRQ Studies of Orphan DrugsDrug Supply Chain Security: H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013 and S. 959, Pharmaceutical Compounding Quality and Accountability Act H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013
Safeguarding America's Pharmaceuticals Act of 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposal Prescription Drug Compounding: S. 959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 2186, VALID Compounding Act; The Compounding Clarity ActDrug Supply Chain Security: S. 959, Pharmaceutical Compounding Quality and Accountability Act, and H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013
Safeguarding America's Pharmaceuticals Act of 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues AHRQ Studies of Orphan DrugsDrug Supply Chain Security: H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013 and S. 959, Pharmaceutical Compounding Quality and Accountability Act H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013 S. 1417, Newborn Screening Saves Lives Reauthorization Act of 2013
Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposal Prescription Drug Compounding: S. 959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 2186, VALID Compounding Act; The Compounding Clarity ActDrug Supply Chain Security: S. 959, Pharmaceutical Compounding Quality and Accountability Act, and H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013
Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposal Prescription Drug Compounding: S. 959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 2186, VALID Compounding Act; The Compounding Clarity ActDrug Supply Chain Security: S. 959, Pharmaceutical Compounding Quality and Accountability Act, and H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013
Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposal S. 959, Pharmaceutical Quality, Security, and Accountability Act H.R. 2186, Verifying Authority and Legality In Drug (VALID) Compounding ActS. 957, Drug Supply Chain Security Act H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013
Preserving Access to Orphan Drugs Act of 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues AHRQ Studies of Orphan DrugsDrug Supply Chain Security H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013 S. 959, Pharmaceutical Quality, Security, and Accountability Act H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013 S. 1417, Newborn Screening Saves Lives Reauthorization Act of 2013 Sequestration of FDA User Fees H.R. 2315, Preserving Access to Orphan Drugs Act of 2013 S. 1128, Preserving Access to Orphan Drugs Act of 2013
To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013
To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013 S. 1871, Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Act of 2013
To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013
To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013 S. 1871, Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Act of 2013
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013
Preserving Access to Orphan Drugs Act of 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues AHRQ Studies of Orphan DrugsDrug Supply Chain Security H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013 S. 959, Pharmaceutical Quality, Security, and Accountability Act H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013 S. 1417, Newborn Screening Saves Lives Reauthorization Act of 2013 Sequestration of FDA User Fees H.R. 2315, Preserving Access to Orphan Drugs Act of 2013 S. 1128, Preserving Access to Orphan Drugs Act of 2013
Medicare Prescription Drug Price Negotiation Act of 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013
Medicare Prescription Drug Price Negotiation Act of 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013
Medicare Prescription Drug Price Negotiation Act of 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013 S. 1871, Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Act of 2013
Medicare Prescription Drug Price Negotiation Act of 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013
Newborn Screening Saves Lives Reauthorization Act of 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues AHRQ Studies of Orphan DrugsDrug Supply Chain Security H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013 S. 959, Pharmaceutical Quality, Security, and Accountability Act H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013 S. 1417, Newborn Screening Saves Lives Reauthorization Act of 2013 Sequestration of FDA User Fees H.R. 2315, Preserving Access to Orphan Drugs Act of 2013 S. 1128, Preserving Access to Orphan Drugs Act of 2013
Newborn Screening Saves Lives Reauthorization Act of 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues AHRQ Studies of Orphan DrugsDrug Supply Chain Security: H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013 and S. 959, Pharmaceutical Compounding Quality and Accountability Act H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013 S. 1417, Newborn Screening Saves Lives Reauthorization Act of 2013
SGR Repeal and Medicare Beneficiary Access Act of 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013 S. 1871, Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Act of 2013
Prescription Drug and Health Improvement Act of 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013
Prescription Drug and Health Improvement Act of 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013
Prescription Drug and Health Improvement Act of 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013
Prescription Drug and Health Improvement Act of 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013 S. 1871, Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Act of 2013
Pharmaceutical Quality, Security, and Accountability Act
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues AHRQ Studies of Orphan DrugsDrug Supply Chain Security: H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013 and S. 959, Pharmaceutical Compounding Quality and Accountability Act H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013
Pharmaceutical Quality, Security, and Accountability Act
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposal Prescription Drug Compounding: S. 959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 2186, VALID Compounding Act; The Compounding Clarity ActDrug Supply Chain Security: S. 959, Pharmaceutical Compounding Quality and Accountability Act, and H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013
Pharmaceutical Quality, Security, and Accountability Act
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposal S. 959, Pharmaceutical Quality, Security, and Accountability Act H.R. 2186, Verifying Authority and Legality In Drug (VALID) Compounding ActS. 957, Drug Supply Chain Security Act H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013
Pharmaceutical Quality, Security, and Accountability Act
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues AHRQ Studies of Orphan DrugsDrug Supply Chain Security: H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013 and S. 959, Pharmaceutical Compounding Quality and Accountability Act H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013 S. 1417, Newborn Screening Saves Lives Reauthorization Act of 2013
Pharmaceutical Quality, Security, and Accountability Act
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposal Prescription Drug Compounding: S. 959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 2186, VALID Compounding Act; The Compounding Clarity ActDrug Supply Chain Security: S. 959, Pharmaceutical Compounding Quality and Accountability Act, and H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013
Pharmaceutical Quality, Security, and Accountability Act
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues AHRQ Studies of Orphan DrugsDrug Supply Chain Security H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013 S. 959, Pharmaceutical Quality, Security, and Accountability Act H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013 S. 1417, Newborn Screening Saves Lives Reauthorization Act of 2013 Sequestration of FDA User Fees H.R. 2315, Preserving Access to Orphan Drugs Act of 2013 S. 1128, Preserving Access to Orphan Drugs Act of 2013
S.606/H.R. 3059 - Creating Hope Act of 2011 Food and Drug Administration Safety and Innovation Act Implementation S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals Report on Innovation/FDA by President's Council of Advisors on Science and Technology (CPAST)
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals
Great Ape Protection and Cost Savings Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposals Report on Innovation/FDA by President's Council of Advisors on Science and Technology (PCAST) H.R. 6433, FDA User Fee Corrections Act H.R. 1513, S. 810, Great Ape Protection & Cost Savings Act of 2011
Generating Antibiotic Incentives Now Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
S.606/H.R. 3059 - Creating Hope Act of 2011 Food and Drug Administration Safety and Innovation Act Implementation S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals Report on Innovation/FDA by President's Council of Advisors on Science and Technology (CPAST)
Generating Antibiotic Incentives Now Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals
Generating Antibiotic Incentives Now Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals
Preserving Access to Life-Saving Medications Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals
Preserving Access to Life-Saving Medications Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals
Preserving Access to Life-Saving Medications Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
S.606/H.R. 3059 - Creating Hope Act of 2011 Food and Drug Administration Safety and Innovation Act Implementation S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals Report on Innovation/FDA by President's Council of Advisors on Science and Technology (CPAST)
FY 2013 Budget Appropriations H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74 H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67 H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36 H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78 H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011 H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011 H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055 H.Con. Res. 112, Establishing the Budget for the U.S. Government for FY2013
Preserving Access to Orphan Drugs Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative Policy Deficit Reduction Proposals to Joint Committee Changes re: Medicare Part B and Average Sales Price H.R. 2672/S. 1423, Preserving Access to Orphan Drugs Act Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program
Preserving Access to Orphan Drugs Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative Policy Deficit Reduction Proposals to Joint Committee Changes re: Medicare Part B and Average Sales Price H.R. 2672/S. 1423, Preserving Access to Orphan Drugs Act Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program
Preserving Access to Orphan Drugs Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative Policy Deficit Reduction Proposals to Joint Committee Changes re: Medicare Part B and Average Sales Price H.R. 2672/S. 1423, Preserving Access to Orphan Drugs Act Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues Drug Supply Chain Security AHRQ Report on Enzyme Replacement Therapy for Lysosomal Storage Diseases H.R. 2674, 340B Program Improvement Act
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues Drug Supply Chain Security AHRQ Report on Enzyme Replacement Therapy for Lysosomal Storage Diseases H.R. 2674, 340B Program Improvement Act
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues Drug Supply Chain Security AHRQ Report on Enzyme Replacement Therapy for Lysosomal Storage Diseases H.R. 2674, 340B Program Improvement Act
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals
S.606/H.R. 3059 - Creating Hope Act of 2011 Food and Drug Administration Safety and Innovation Act Implementation S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals Report on Innovation/FDA by President's Council of Advisors on Science and Technology (CPAST)
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals
Consolidated Appropriations Act, 2012
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
FY 2013 Budget H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74 H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78 H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011, Pub. L. 112-96 H.Con. Res. 112, Establishing the Budget for the U.S. Government for FY2013 H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act H.J. Res. 117, Continuing Appropriations Resolution, 2013
Consolidated Appropriations Act, 2012
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
FY 2013 Budget Appropriations H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74 H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67 H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36 H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78 H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011 H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011 H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055 H.Con. Res. 112, Establishing the Budget for the U.S. Government for FY2013
Consolidated Appropriations Act, 2012
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
FY 2013 Budget H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74 H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78 H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011, Pub. L. 112-96 H.Con. Res. 112, Establishing the Budget for the U.S. Government for FY2013 H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals
S.606/H.R. 3059 - Creating Hope Act of 2011 Food and Drug Administration Safety and Innovation Act Implementation S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals Report on Innovation/FDA by President's Council of Advisors on Science and Technology (CPAST)
Temporary Payroll Tax Cut Continuation Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
FY 2013 Budget Appropriations H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74 H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67 H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36 H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78 H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011 H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011 H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055 H.Con. Res. 112, Establishing the Budget for the U.S. Government for FY2013
Temporary Payroll Tax Cut Continuation Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
FY 2013 Budget H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74 H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78 H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011, Pub. L. 112-96 H.Con. Res. 112, Establishing the Budget for the U.S. Government for FY2013 H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act H.J. Res. 117, Continuing Appropriations Resolution, 2013
Temporary Payroll Tax Cut Continuation Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
FY 2013 Budget Appropriations H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74 H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67 H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36 H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78 H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011 H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011 H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055 H.Con. Res. 112, Establishing the Budget for the U.S. Government for FY2013
Temporary Payroll Tax Cut Continuation Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
FY 2013 Budget H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74 H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78 H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011, Pub. L. 112-96 H.Con. Res. 112, Establishing the Budget for the U.S. Government for FY2013 H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals
S.606/H.R. 3059 - Creating Hope Act of 2011 Food and Drug Administration Safety and Innovation Act Implementation S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals Report on Innovation/FDA by President's Council of Advisors on Science and Technology (CPAST)
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals
S.606/H.R. 3059 - Creating Hope Act of 2011 Food and Drug Administration Safety and Innovation Act Implementation S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals Report on Innovation/FDA by President's Council of Advisors on Science and Technology (CPAST)
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
FY 2013 Budget H.Con. Res. 112, Establishing the Budget for the U.S. Government for FY2013 H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act H.J. Res. 117, Continuing Appropriations Resolution, 2013
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
FY 2013 Budget H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74 H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78 H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011, Pub. L. 112-96 H.Con. Res. 112, Establishing the Budget for the U.S. Government for FY2013 H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act H.J. Res. 117, Continuing Appropriations Resolution, 2013
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
FY 2013 Budget H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74 H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78 H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011, Pub. L. 112-96 H.Con. Res. 112, Establishing the Budget for the U.S. Government for FY2013 H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act
FDA User Fee Corrections Act of 2012
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposals Report on Innovation/FDA by President's Council of Advisors on Science and Technology (PCAST) H.R. 6433, FDA User Fee Corrections Act H.R. 1513, S. 810, Great Ape Protection & Cost Savings Act of 2011
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative Policy Changes re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues H. Con. Res. 112, Budget Resolution H.R. 6684, Spending Reduction Act of 2012 H.R. 8, American Taxpayer Relief Act Delay of Oral-Only Drugs in the ESRD bundle
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics Extension of R& D Tax Credit H.R.942, American Research and Competitiveness Act S. 1577 Greater Research Opportunities with Tax Help Act H.R. 8, American Taxpayer Relief Act of 2012
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative Policy Changes re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues H. Con. Res. 112, Budget Resolution H.R. 6684, Spending Reduction Act of 2012 H.R. 8, American Taxpayer Relief Act Delay of Oral-Only Drugs in the ESRD bundle
American Research and Competitiveness Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics Extension of R& D Tax Credit H.R.942, American Research and Competitiveness Act S. 1577 Greater Research Opportunities with Tax Help Act H.R. 8, American Taxpayer Relief Act of 2012
American Research and Competitiveness Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics Extension of R& D Tax Credit H.R.942, American Research and Competitiveness Act S. 1577 Greater Research Opportunities with Tax Help Act
American Research and Competitiveness Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics Extension of R& D Tax Credit H.R.942, American Research and Competitiveness Act S. 1577 Greater Research Opportunities with Tax Help Act
American Research and Competitiveness Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics Extension of R& D Tax Credit H.R.942, American Research and Competitiveness Act S. 1577 Greater Research Opportunities with Tax Help Act
Preserving Access to Life-Saving Medications Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 2482, Drug Safety Enhancement Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals
Preserving Access to Life-Saving Medications Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 2482, Drug Safety Enhancement Act
Preserving Access to Life-Saving Medications Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
S.606 - Creating Hope Act of 2011 Prescription Drug User Fee Act reauthorization S.296/H.R.2245 Preserving Access to Life-Saving Medication Act H.R.2482 Drug Safety Enhancement Act
Public Safety Spectrum and Wireless Innovation Act
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
S.606 - Creating Hope Act of 2011 Prescription Drug User Fee Act reauthorization S.296/H.R.2245 Preserving Access to Life-Saving Medication Act H.R.2482 Drug Safety Enhancement Act
Public Safety Spectrum and Wireless Innovation Act
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 2482, Drug Safety Enhancement Act
Public Safety Spectrum and Wireless Innovation Act
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 2482, Drug Safety Enhancement Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals
FY 2012 Budget Appropriations H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74 H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67 H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36 H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78 H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011 H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011 H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055
Preserving Access to Orphan Drugs Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative Policy Deficit Reduction Proposals to Joint Committee Changes re: Medicare Part B and Average Sales Price H.R. 2672/S. 1423, Preserving Access to Orphan Drugs Act Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs
Preserving Access to Orphan Drugs Act of 2011
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative Policy Deficit Reduction Proposals to Joint Committee Changes re: Medicare Part B and Average Sales Price H.R. 2672/S.1423, Preserving Access to Orphan Drugs Act Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 2482, Drug Safety Enhancement Act
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 2482, Drug Safety Enhancement Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals
Consolidated Appropriations Act, 2012
Client: GENZYME CORPORATION · Firm: GENZYME CORPORATION
FY 2012 Budget Appropriations H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74 H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67 H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36 H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78 H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011 H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011 H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055
FY 2014 Budget H.J. Res. 59, Continuing Appropriations Resolution for FY 2014, including Funding for FDA
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics Extension of R& D Tax Credit Orphan Drug Tax CreditImplementation of American Taxpayer Relief Act of 2012 Tax Reform
Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposal S. 959, Pharmaceutical Quality, Security, and Accountability Act H.R. 2186, Verifying Authority and Legality In Drug (VALID) Compounding ActS. 957, Drug Supply Chain Security Act H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENZYME CORPORATION via GENZYME CORPORATION
2013 · third_quarter · Q3
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues AHRQ Studies of Orphan DrugsDrug Supply Chain Security: H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013 and S. 959, Pharmaceutical Compounding Quality and Accountability Act H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013 S. 1417, Newborn Screening Saves Lives Reauthorization Act of 2013
FY 2013 Budget FY 2014 Budget FY 2013 Appropriations - Labor-HHS, Agriculture and FDA
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics Extension of R& D Tax Credit Orphan Drug Tax CreditImplementation of American Taxpayer Relief Act of 2012 Tax Reform
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013
Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposal Prescription Drug Compounding: S. 959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 2186, VALID Compounding Act; The Compounding Clarity ActDrug Supply Chain Security: S. 959, Pharmaceutical Compounding Quality and Accountability Act, and H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENZYME CORPORATION via GENZYME CORPORATION
2013 · second_quarter · Q2
Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposal Prescription Drug Compounding: S. 959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 2186, VALID Compounding Act; The Compounding Clarity ActDrug Supply Chain Security: S. 959, Pharmaceutical Compounding Quality and Accountability Act, and H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics Extension of R& D Tax Credit Orphan Drug Tax CreditImplementation of American Taxpayer Relief Act of 2012 Tax Reform
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues AHRQ Studies of Orphan DrugsDrug Supply Chain Security: H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013 and S. 959, Pharmaceutical Compounding Quality and Accountability Act H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013
FY 2013 Budget FY 2014 Budget FY 2013 Appropriations - Labor-HHS, Agriculture and FDA
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENZYME CORPORATION via GENZYME CORPORATION
2013 · first_quarter · Q1
Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposal
FY 2013 Budget FY 2014 Budget
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics Extension of R& D Tax Credit Orphan Drug Tax CreditImplementation of American Taxpayer Relief Act of 2012
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues Drug Supply Chain SecurityH.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013 AHRQ Studies of Orphan Drugs
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENZYME CORPORATION via GENZYME CORPORATION
2012 · fourth_quarter · Q4
Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposals Report on Innovation/FDA by President's Council of Advisors on Science and Technology (PCAST) H.R. 6433, FDA User Fee Corrections Act H.R. 1513, S. 810, Great Ape Protection & Cost Savings Act of 2011
TPP, Trade Negotiations and Protection of Biological Product Exclusivity
FY 2013 Budget H.Con. Res. 112, Establishing the Budget for the U.S. Government for FY2013 H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act H.J. Res. 117, Continuing Appropriations Resolution, 2013
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues Drug Supply Chain Security AHRQ Report on Enzyme Replacement Therapy for Lysosomal Storage Diseases H.R. 2674, 340B Program Improvement Act
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative Policy Changes re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues H. Con. Res. 112, Budget Resolution H.R. 6684, Spending Reduction Act of 2012 H.R. 8, American Taxpayer Relief Act Delay of Oral-Only Drugs in the ESRD bundle
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics Extension of R& D Tax Credit H.R.942, American Research and Competitiveness Act S. 1577 Greater Research Opportunities with Tax Help Act H.R. 8, American Taxpayer Relief Act of 2012
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENZYME CORPORATION via GENZYME CORPORATION
2012 · third_quarter · Q3
S.606/H.R. 3059 - Creating Hope Act of 2011 Food and Drug Administration Safety and Innovation Act Implementation S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals Report on Innovation/FDA by President's Council of Advisors on Science and Technology (CPAST)
H.R. 1249/S. 23, the America Invents Act TPP, Trade Negotiations and Protection of Biological Product Exclusivity
GENZYME CORPORATION via GENZYME CORPORATION
2012 · second_quarter · Q2
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues Drug Supply Chain Security AHRQ Report on Enzyme Replacement Therapy for Lysosomal Storage Diseases H.R. 2674, 340B Program Improvement Act
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals
GENZYME CORPORATION via GENZYME CORPORATION
2012 · first_quarter · Q1
H.R. 1249/S. 23, the America Invents Act
FY 2013 Budget Appropriations H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74 H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67 H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36 H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78 H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011 H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011 H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055 H.Con. Res. 112, Establishing the Budget for the U.S. Government for FY2013
GENZYME CORPORATION via GENZYME CORPORATION
2011 · fourth_quarter · Q4
H.R. 1249/S. 23, the America Invents Act
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 2482, Drug Safety Enhancement Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues Drug Supply Chain Security AHRQ Report on Enzyme Replacement Therapy for Lysosomal Storage Diseases
GENZYME CORPORATION via GENZYME CORPORATION
2011 · third_quarter · Q3
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 2482, Drug Safety Enhancement Act
H.R. 1249/S. 23, America Invents Act
GENZYME CORPORATION via GENZYME CORPORATION
2011 · second_quarter · Q2
S.606 - Creating Hope Act of 2011 Prescription Drug User Fee Act reauthorization S.296/H.R.2245 Preserving Access to Life-Saving Medication Act H.R.2482 Drug Safety Enhancement Act
Implemenation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics
H.R. 1249/S.23, America Invents Act
GENZYME CORPORATION via GENZYME CORPORATION
2011 · first_quarter · Q1
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative Policy
H.R. 1249/S. 23, the America Invents Act
S.606 - Creating Hope Act of 2011 Prescription Drug User Fee Act Renewal S. 296: Preserving Access to Life-Saving Medications Act
GENZYME CORPORATION via GENZYME CORPORATION
2010 · fourth_quarter · Q4
P.L. 111-152, Health Care and Education Reconciliation Act of 2010 H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011 H.R. 3082, Continuing Appropriations and Surface Transportation Extensions Act, 2011; PL 111-322 H.J.RES.105, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-317 H.J.RES.101, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-290
H.R. 444, 340B Program Improvement and Integrity Act of 2009, 340B drug price expansion ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Reimbursement for Part B Drugs Administered in Hospital Out-patient Departments, Dialysis Centers and Physician Offices Physician Fee Schedule Payment Rates for Lab Tests Medicaid Rebates Implementation of MIPPA H.R. 1699, Patient Access to Critical Lab Test H.R. 1452, Medicare Clinical Diagnostic Laboratory Fee Schedule Modernization Act of 2009 Reimbursement /Payment Laboratory Tests H.R. 676, US National Health Care Act or the Expanded and Improved Medicare for All Act Reimbursement for Clinical Lab Tests Reimbursement for Medicare Part D Drugs P.L. 111-148, Patient Protection & Affordable Health Care Act P.L. 111-152, Health Care and Education Reconciliation Act of 2010 S. 11, To Restore the Application of the 340B Drug Discount Program to Orphan Drugs with Respect to Children's Hospitals S. Amendment (Baucus) to H.R. 4848, Small Business and Infrastructure Jobs Tax Act of 2010 (340B Provisions) H.R. 1586, Education Jobs and Medicaid Funding Bill (AMP Revisions) H.R. 4899, Supplemental Appropriations Act 2010 (AMP Revisions) H.R.5712, Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Children's Hospitals Provision) Health Care Reform Implementation Issues
GENZYME CORPORATION via GENZYME CORPORATION
2010 · third_quarter · Q3
H.R. 444, 340B Program Improvement and Integrity Act of 2009, 340B drug price expansion ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Reimbursement for Part B Drugs Administered in Hospital Out-patient Departments, Dialysis Centers and Physician Offices Physician Fee Schedule Payment Rates for Lab Tests Medicaid Rebates Implementation of MIPPA H.R. 1699, Patient Access to Critical Lab Test H.R. 1452, Medicare Clinical Diagnostic Laboratory Fee Schedule Modernization Act of 2009 Reimbursement /Payment Laboratory Tests H.R. 676, US National Health Care Act or the Expanded and Improved Medicare for All Act Reimbursement for Clinical Lab Tests Reimbursement for Medicare Part D Drugs P.L. 111-148, Patient Protection & Affordable Health Care Act P.L. 111-152, Health Care and Education Reconciliation Act of 2010 S. 11, To Restore the Application of the 340B Drug Discount Program to Orphan Drugs with Respect to Children's Hospitals S. Amendment (Baucus) to H.R. 4848, Small Business and Infrastructure Jobs Tax Act of 2010 (340B Provisions) H.R. 1586, Education Jobs and Medicaid Funding Bill (AMP Revisions) H.R. 4899, Supplemental Appropriations Act 2010 (AMP Revisions) H.R.5712, Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Children's Hospitals Provision) Health Care Reform Implementation Issues
GENZYME CORPORATION via GENZYME CORPORATION
2010 · second_quarter · Q2
H.R. 4872, Health Care and Education Reconciliation Act of 2010
H.R. 3156, Neglected Disease Tax Credit Bill Excise Tax for Medical Devices H.R. 3962, Preservation of Access to Care for Medicare Beneficiaries and Pension Relief Act of 2010 H.R. 3590, Patient Protection & Affordable Health Care Act H.R. 4872, Health Care and Education Reconciliation Act of 2010
H.R. 1452, Medicare Clinical Diagnostic Laboratory Fee Schedule Modernization Act of 2009 Reimbursement for Clinical Lab Services under Medicare Excise Tax for Laboratory Services H.R. 3962, Preservation of Access to Care for Medicare Beneficiaries and Pension Relief Act of 2010 H.R. 3590, Patient Protection & Affordable Health Care Act
GENZYME CORPORATION via GENZYME CORPORATION
2010 · first_quarter · Q1
S. 515, Patent Reform Act of 2009 H.R. 1260, Patent Reform Act of 2009 H.R. 1548, Pathway for Biosimilars Act of 2009 H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act, Follow-on Biologics S. 726, Promoting Innovation and Access to Life-Saving Medicines Act, Follow-on Biologics S. 610, Patent Reform Act of 2009 S. 1679, America's Affordable Health Choices Act of 2009 H.R. 3962, Affordable Health Care for Americans Act H.R. 3590, Patient Protection & Affordable Health Care Act
H.R. 3156, Neglected Disease Tax Credit Bill Excise tax for laboratory tests Excise tax for drugs Excise tax for medical devices H.R. 3200, America's Affordable Health Choices Act of 2009 H.R. 3962, Affordable Health Care for Americans Act H.R. 3590, Patient Protection & Affordable Health Care Act H.R. 4872, Health Care and Education Reconciliation Act of 2010
GENZYME CORPORATION via GENZYME CORPORATION
2009 · fourth_quarter · Q4
H.R. 3156, Neglected Disease Tax Credit Bill Excise Tax for laboratory tests Excise Tax for drugs Excise Tax for medical devices House Tri-Caucus Health Reform Bill Senate Finance Health Reform Bill H.R. 3200, America's Affordable Health Choices Act of 2009 H.R. 3962, Affordable Health Care for Americans Act H.R. 3590, Patient Protection & Affordable Health Care Act
H.R. 1 American Recovery and Reinvestment Act of 2009 S. Con. Res. 13 H.R.. Con. Res. 85 H.R. 3288, Consolidated Appropriations Act, 2010, LHHS - Division D FDA, Homeland Security Appropriations H.R. 2997, Agriculture (FDA) Appropriations H.R. 2892, Homeland Security Appropriations
GENZYME CORPORATION via GENZYME CORPORATION
2009 · third_quarter · Q3
H.R. 3156, Neglected Disease Tax Credit Bill Excise Tax for laboratory tests Excise Tax for drugs Excise Tax for medical devices House Tri-Caucus Health Reform Bill Senate Finance Health Reform Bill H.R. 3200, America's Affordable Health Choices Act of 2009
H.R. 1 American Recovery and Reinvestment Act of 2009 S. Con. Res. 13 H.R.. Con. Res. 85 S. 350 American Recovery and Reinvestment Act of 2009 FDA, Homeland Security Appropriations H.R. 2997, Agriculture (FDA) Appropriations H.R. 2892, Homeland Security Appropriations
H.R. 444, 340B Program Improvement and Integrity Act of 2009, 340B drug price expansion H.R. 1832, Medicare Prescription Drug Affordability Act of 2009 S. 266, Medicare Prescription Drug Gap Reduction Act of 2009 S. 301, Physician Payments Sunshine Act of 2009 Comparative Effectiveness ESRD "bundling issues" and ESRD drug reimbursement issues Medicare prescription drug benefit CPT Coding decisions and HCPCS coding decisions Reimbursement for Part B Drugs administered in hospital out patient departments, dialysis centers and physician officers Physicians fee schedule payment rates for lab tests Medicaid rebates MIPPA Technical Corrections H.R. 1699 Patient Access to Critical Lab Test H.R. 1452 Medicare Clinical Diagnostic Laboratory Fee Schedule Modernization Act of 2009 Reimbursement /Payment laboratory tests S. 275 Children's Health Insurance Program Reauthorization Act of 2009 H.R. 2 Children's Health Insurance Program Reauthorization Act of 2009 H.R. 676 - US National Health Care Act or the Expanded and Improved Medicare for All Act Least Costly Alternative (LCA) policy for viscosupplements Kennedy Health Reform Bill House Tri-Committee Health Reform Bill Senate Finance Health Reform Bill S. 1110, Medicare Payment Advisory Commission Reform Act of 2009 H.R. 2502, Comparative Effectiveness Research Act of 2009 S. 1213, Patient Centered Outcomes Research Act of 2009 H.R. 3200, America's Affordable Health Choices Act of 2009 Reimbursement for Clinical Lab Tests Reimbursement for Medicare Part D Drugs
GENZYME CORPORATION via GENZYME CORPORATION
2009 · second_quarter · Q2
Neglected Disease Tax Credit
H.R. 1548, Pathway for Biosimilars Act of 2009 H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act S. 726 Promoting Innovation and Access to Life-Saving Medicines Act S. 301 Physician Payments Sunshine Act of 2009 Neglected Disease Issues Issues related to Drug Safety, Generic Biologics & Drug Approvals Importation. H.R. 1298, Pharmaceutical Market Access & Drug Safety Act of 2009" - Importation. S.525, "Pharmaceutical Market Access & Drug Safety Act of 2009" - Importation H.R. 759, Food and Drug Administration Globalization Act of 2009
GENZYME CORPORATION via GENZYME CORPORATION
2009 · first_quarter · Q1
H.R. 1452, Medicare Clinical Diagnostic laboratory Fee Schedule Modernization Act of 2009 Reimbursement for clinical lab services under Medicare
H.R. 1 American Recovery and Reinvestment Act of 2009 S. Con. Res. 13 H. Con. Res. 85 S. 350 American Recovery and Reinvestment Act of 2009
Neglected Disease Tax Credit
GENZYME CORPORATION via GENZYME CORPORATION
2008 · fourth_quarter · Q4
H.R. 3453, Community Clinical Laboratory Fairness in Competition Act of 2007 Reimbursement for clinical lab services under Medicare H.R. 1321 "Medicare Advanced Laboratory Diagnostics Act"; S.2404 "The Medicare Advanced Laboratory Diagnostic Act of 2007" S.976 "Genomics & Personalized Medicine Act of 2007" Competitive bidding for lab tests S.736, "The Laboratory Test Improvement Act"
H.R. 2606, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion H.R. 3162, Children's Health and Medicare Protection Act of 2007 H.R. 4, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provisions H.R. 5480 Medicare Funding Warning Response Act of 2008 S. 1376, 340B Program Improvement and Integrity Act of 2007, 340B Drug price expansion S. 2029, Physician Payments Sunshine Act of 2007 S. 2662, Medicare Funding Warning Response Act of 2008 S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provision Comparative Effectiveness S. 2099 "Preserving Access to Laboratory Services Act of 2007" Repeal of Competitive bidding demo ESRD "bundling issues" and ESRD drug reimbursement issues Medicare prescription drug benefit H.R. 1321 "Medicare Advanced Laboratory Diagnostic Act of 2007" S. 691/H.R. 1193 The Kidney Care Quality and Education Act CPT Coding decisions and HCPCS coding decisions Reimbursement for Part B Drugs administered in hospital out patient departments, dialysis centers and physician officers Physicians fee schedule payment rates for lab tests. Medicaid rebates H.R. 2184, The Enhanced health Care Value for All Act H.R. 6331 "Medicare Improvements for Patients and Providers Act of 2008" S. 3101, "Medicare Improvements for Patients and Providers Act of 2008" MIPPA Technical Connections H.R. 1472 Emergency Economic Stabilization Act of 2008
GENZYME CORPORATION via GENZYME CORPORATION
2008 · third_quarter · Q3
H.R. 2606, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion H.R. 3162, Children's Health and Medicare Protection Act of 2007 H.R. 4, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provisions H.R. 5480 Medicare Funding Warning Response Act of 2008 S. 1376, 340B Program Improvement and Integrity Act of 2007, 340B Drug price expansion S. 2029, Physician Payments Sunshine Act of 2007 S. 2662, Medicare Funding Warning Response Act of 2008 S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provision Comparative Effectiveness S. 2099 "Preserving Access to Laboratory Services Act of 2007" Repeal of Competitive bidding demo ESRD "bundling issues" and ESRD drug reimbursement issues Medicare prescription drug benefit H.R. 1321 "Medicare Advanced Laboratory Diagnostic Act of 2007" S. 691/H.R. 1193 The Kidney Care Quality and Education Act CPT Coding decisions and HCPCS coding decisions Reimbursement for Part B Drugs administered in hospital out patient departments, dialysis centers and physician officers Physicians fee schedule payment rates for lab tests. Medicaid rebates H.R. 2184, The Enhanced health Care Value for All Act H.R. 6331 "Medicare Improvements for Patients and Providers Act of 2008" S. 3101, "Medicare Improvements for Patients and Providers Act of 2008" MIPPA Technical Connections H.R. 1472 Emergency Economic Stabilization Act of 2008
GENZYME CORPORATION via GENZYME CORPORATION
2008 · second_quarter · Q2
S. 1145, Patent Reform Act of 2007 HR. 1908, Patent Reform Act of 2007 H.R. 1038, Access to Life-Saving Medicine Act, Follow-on biologics H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics H.R. 5629, Pathway for Biosimilars Act S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on Biologics S. 623, Access to Life-Saving Medicine Act, follow-on biologics
H.R. 2606, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion H.R. 3162, Children's Health and Medicare Protection Act of 2007 H.R. 4, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provisions H.R. 5480m Medicare Funding Warning Response Act of 2008 S. 1376, 340B Program Improvement and Integrity Act of 2007, 340B Drug price expansion S. 2029, Physician Payments Sunshine Act of 2007 S. 2662, Medicare Funding Warning Response Act of 2008 S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provision Comparative Effectiveness S. 2099 "Preserving Access to Laboratory Services Act of 2007" Repeal of competitive bidding demo ESRD "bundling issues" and ESRD drug reimbursement issues Medicare prescription drug benefit H.R. 1321 "Medicare Advanced Laboratory Diagnostic Act of 2007" S.2404 "The Medicare Advanced Laboratory Diagnostic Act of 2007" S. 691/H.R. 1193 The Kidney Care Quality and Education Act CPT Coding decisions and HCPCS coding decisions Reimbursement for Part B Drugs administered in hospital outpatient departments, dialysis centers and physician officers Physicians fee schedule payment rates for lab tests. Medicaid rebates H.R. 2184, the Enhanced health Care Value for All Act H.R. 6331 "Medicare Improvements for Patients and Providers Act of 2008" S.3101, "Medicare Improvements for Patients and Providers Act of 2008"
GENZYME CORPORATION via GENZYME CORPORATION
2008 · first_quarter · Q1
H.R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics H.R. 5629, Pathway for Biosimilars Act S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, Follow-on Biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 623, Access to Life-Saving Medicine Act, follow-on biologics Neglected Disease Issues Issues related to Drug Safety, Generic Biologics & Drug Approvals H.R. 380, "Pharmaceutical Market Access and Drug Safety act of 2007" - Importation. S.251, Pharmaceutical Market Access & Drug Safety Act of 2007" - Importation. S.242, "Pharmaceutical Market Access & Drug Safety Act of 2007" H.R. 1561, Enhancing Drug Safety and Innovation Act of 2007
H.R. 3453, Community Clinical Laboratory Fairness in Competition Act of 2007 Reimbursement for clinical lab services under Medicare H.R. 1321 "Medicare Advanced Laboratory Diagnostics Act"; S.2404 "The Medicare Advanced Laboratory Diagnostic Act of 2007" S.976 "Genomics & Personalized Medicine Act of 2007" Competitive bidding for lab tests S.736, "The Laboratory Test Improvement Act"
GENZYME CORPORATION via GENZYME CORPORATION
2007 · year_end · YY
a) H.R. 3453, Community Clinical Laboratory Fairness in Competition Act of 2007 b) Reimbursement for clinical lab services under Medicare c) H.R. 1321 "Medicare Advanced Laboratory Diagnostics Act"; S.2404 "The Medicare Advanced Laboratory Diagnostic Act of 2007"
a) H.R. 3043, Labor HHS-Education and Related Agencies Appropriations Act (Medicare and health care provisions) b) S.1710 Labor HHS-Education and Related Agencies Appropriations Act (Medicare and Health care provisions) c) Medicare prescription drug benefit, including reimbursement for orphan drugs d) H.R. 1321 "Medicare Advanced Laboratory Diagnostics Act of 2007", reimbursement for lab tests; S.2404 "The Medicare
GENZYME CORPORATION via GENZYME CORPORATION
2007 · mid_year · MM
e) Patent reform issues. f) H.R. 1908 "Patent Reform Act of 2007" g) S.1145, "Patent Reform Act of 2007" a) Patent framework affecting generic biologics. b) S.1695, "Biologics Price Competition and Innovation Act of 2007 c) S.623, "Access to Life-Saving Medicine Act" d) H.R. 1038, Access to Life-Saving Medicine Act"
e) S.1082 "FDA Revitalization Act of 2007" Provision Re: IOM Lab Study f) S.736, "The Laboratory Test Improvement Act" a) Reimbursement for clinical lab services under Medicare. b) H.R. 1321 "Medicare Advanced Laboratory Diagnostics Act" c) S.976 "Genomics & Personalized Medicine Act of 2007" d) Competitive bidding for lab tests
GENZYME CORPORATION via GENZYME CORPORATION
2006 · year_end · YY
Tax incentives for neglected disease research.
c) Reimbursement for Part B Drugs administered in hospital outpatient departments, dialysis centers and physician offices. d) Implementation of the Competitive Acquisition (CAP) Program for Part B Drugs. e) 340B Programs. f) H.R. 4241, "Deficit Reduction Act of 2005". g) S. 1932, "Deficit Reduction Omnibus Reconciliation Act of 2005". h) CMS guidance on coverage under evidence development. i) Physicians fee schedule payment rates for lab tests. j) Medicaid budget reductions. k) H.R. 6408, "Tax Relief and Health Care Act of 2006". l) Medicaid rebates a) Medicare Prescription Drug Benefit: Implementation of issues associated w/P.L. 108-173, including reimbursement for orphan drugs. b) HCPCS Workgroup Coding Decisions.
GENZYME CORPORATION via GENZYME CORPORATION
2006 · year_end · YY
Tax incentives for neglected disease research.
e) S. 109, "Pharmaceutical Market Access Act of 2005". f) S. 334, "Pharmaceutical Market Access & Drug Safety Act of 2005". g) Issues related to clinical trial data bank. h) S. 470, H.R. 3196, "Fair Access to Clinical Trials Act". i) H.R. 6257, "Access to Life-Saving Medicines Act". a) Issues related to Drug Safety, Generic Biologics & Drug Approvals, FDA User Fees. b) S.930, "Food & Drug Administration Act of 2005". c) H.R. 2090, "Food & Drug Administration Improvement Act of 2005". d) H.R. 700, "Pharmaceutical Market Access & Drug Safety Act of 2005" - Importation.
GENZYME CORPORATION via GENZYME CORPORATION
2006 · mid_year · MM
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues Drug Supply Chain Security AHRQ Report on Enzyme Replacement Therapy for Lysosomal Storage Diseases H.R. 2674, 340B Program Improvement Act
FY 2013 Budget H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74 H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78 H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011, Pub. L. 112-96 H.Con. Res. 112, Establishing the Budget for the U.S. Government for FY2013 H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act H.J. Res. 117, Continuing Appropriations Resolution, 2013
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative Policy Deficit Reduction Proposals to Joint Committee Changes re: Medicare Part B and Average Sales Price H.R. 2672/S. 1423, Preserving Access to Orphan Drugs Act Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics Extension of R& D Tax Credit H.R.942, American Research and Competitiveness Act S. 1577 Greater Research Opportunities with Tax Help Act
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 1249/S. 23, the America Invents Act
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics Extension of R& D Tax Credit H.R.942, American Research and Competitiveness Act S. 1577 Greater Research Opportunities with Tax Help Act
FY 2013 Budget H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74 H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78 H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011, Pub. L. 112-96 H.Con. Res. 112, Establishing the Budget for the U.S. Government for FY2013 H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative Policy Deficit Reduction Proposals to Joint Committee Changes re: Medicare Part B and Average Sales Price H.R. 2672/S. 1423, Preserving Access to Orphan Drugs Act Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S.606/H.R. 3059 - Creating Hope Act of 2011 Prescription Drug User Fee Act Reauthorization S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act H.R. 1483, Drug Safety Enhancement Act H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act H.R. 4132, FAST (Faster Access to Specialized Treatments) Act Amendments to FDA Accelerated Approval Requirements H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act S. 1734, Generating Antibiotic Incentives Now Act Biosimilars User Fees Biosimilars Exclusivity Period in Administration's Budget Proposals
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues Drug Supply Chain Security AHRQ Report on Enzyme Replacement Therapy for Lysosomal Storage Diseases
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics Extension of R& D Tax Credit H.R.942, American Research and Competitiveness Act S. 1577 Greater Research Opportunities with Tax Help Act
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative Policy Deficit Reduction Proposals to Joint Committee Changes re: Medicare Part B and Average Sales Price H.R. 2672/S. 1423, Preserving Access to Orphan Drugs Act Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics
FY 2012 Budget Appropriations H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74 H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68 H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67 H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36 H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78 H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011 H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011 H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative Policy Deficit Reduction Proposals to Joint Committee Changes re: Medicare Part B and Average Sales Price H.R. 2672/S. 1423, Preserving Access to Orphan Drugs Act Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative Policy Deficit Reduction Proposals to Joint Committee Changes re: Medicare Part B and Average Sales Price H.R. 2672/S.1423, Preserving Access to Orphan Drugs Act Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative policy Deficit reduction proposals related to debt ceiling
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 1452, Medicare Clinical Diagnostic Laboratory Fee Schedule Modernization Act of 2009 Reimbursement for Clinical Lab Services under Medicare Excise Tax for Laboratory Services P.L. 111-148, Patient Protection & Affordable Health Care Act
S. 515, Patent Reform Act of 2009 H.R. 1260, Patent Reform Act of 2009 S. 610, Patent Reform Act of 2009 S. 3677 Financial Services and General Appropriations Act 2011 (Patent Settlement Provisions)
H.R. 3156, Neglected Disease Tax Credit Bill Excise Tax for Medical Devices P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics P.L. 111-152, Health Care and Education Reconciliation Act of 2010
H.R. 3156, Neglected Disease Tax Credit Bill H.R. 759, Food and Drug Administration Globalization Act of 2009 P.L. 111-148, Patient Protection & Affordable Health Care Act Treatment of Orphan Drugs Under 340B Expansion P.L. 111-152, Health Care and Education Reconciliation Act of 2010 H.R. 3081, Continuing Appropriations Act of 2011 (340B Provisions) S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
H.R. 3156, Neglected Disease Tax Credit Bill H.R. 759, Food and Drug Administration Globalization Act of 2009 P.L. 111-148, Patient Protection & Affordable Health Care Act Treatment of Orphan Drugs Under 340B Expansion P.L. 111-152, Health Care and Education Reconciliation Act of 2010 H.R. 3081, Continuing Appropriations Act of 2011 (340B Provisions)
S. 515, Patent Reform Act of 2009 H.R. 1260, Patent Reform Act of 2009 S. 610, Patent Reform Act of 2009 S. 3677 Financial Services and General Appropriations Act 2011 (Patent Settlement Provisions)
P.L. 111-152, Health Care and Education Reconciliation Act of 2010
H.R. 3156, Neglected Disease Tax Credit Bill Excise Tax for Medical Devices P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics P.L. 111-152, Health Care and Education Reconciliation Act of 2010
H.R. 1452, Medicare Clinical Diagnostic Laboratory Fee Schedule Modernization Act of 2009 Reimbursement for Clinical Lab Services under Medicare Excise Tax for Laboratory Services P.L. 111-148, Patient Protection & Affordable Health Care Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
H.R. 444, 340B Program Improvement and Integrity Act of 2009, 340B drug price expansion ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Reimbursement for Part B Drugs Administered in Hospital Out-patient Departments, Dialysis Centers and Physician Offices Physician Fee Schedule Payment Rates for Lab Tests Medicaid Rebates Implementation of MIPPA H.R. 1699, Patient Access to Critical Lab Test H.R. 1452, Medicare Clinical Diagnostic Laboratory Fee Schedule Modernization Act of 2009 Reimbursement /Payment Laboratory Tests H.R. 676, US National Health Care Act or the Expanded and Improved Medicare for All Act Reimbursement for Clinical Lab Tests Reimbursement for Medicare Part D Drugs H.R. 3962, Preservation of Access to Care for Medicare Beneficiaries and Pension Relief Act of 2010 H.R. 3590, Patient Protection & Affordable Health Care Act H.R. 4872, Health Care and Education Reconciliation Act of 2010 H.R. 4851, Continuing Extension Act of 2010 H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010 H.R. 2847, Hiring Incentives to Restore Employment Act Health Care Reform Implementation Issues
H.R. 3156, Neglected Disease Tax Credit Bill H.R. 759, Food and Drug Administration Globalization Act of 2009 H.R. 3590, Patient Protection & Affordable Health Care Act Treatment of Orphan Drugs Under 340B Expansion H.R. 4872, Health Care and Education Reconciliation Act of 2010
S. 515, Patent Reform Act of 2009 H.R. 1260, Patent Reform Act of 2009 S. 610, Patent Reform Act of 2009
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
H.R. 1548, Pathway for Biosimilars Act of 2009 H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act S. 726, Promoting Innovation and Access to Life-Saving Medicines Act S. 301, Physician Payments Sunshine Act of 2009 H.R. 3156, Neglected Disease Tax Credit Bill H.R. 1298, Pharmaceutical Market Access & Drug Safety Act of 2009" - Importation. S.525, "Pharmaceutical Market Access & Drug Safety Act of 2009" - Importation H.R. 759, Food and Drug Administration Globalization Act of 2009 S. 1679, America's Affordable Health Choices Act of 2009 H.R. 3962, Affordable Health Care for Americans Act H.R. 3590, Patient Protection & Affordable Health Care Act Treatment of Orphan Drugs Under 340B Expansion H.R. 4872, Health Care and Education Reconciliation Act of 2010
H.R. 444, 340B Program Improvement and Integrity Act of 2009, 340B drug price expansion H.R. 1832, Medicare Prescription Drug Affordability Act of 2009 S. 266, Medicare Prescription Drug Gap Reduction Act of 2009 S. 301, Physician Payments Sunshine Act of 2009 ESRD "bundling issues" and ESRD drug reimbursement issues HCPCS coding decisions Reimbursement for Part B drugs administered in hospital out patient departments, dialysis centers and physician offices Physician fee schedule payment rates for lab tests Medicaid rebates Implementation of MIPPA H.R. 1699, Patient Access to Critical Lab Test H.R. 1452, Medicare Clinical Diagnostic Laboratory Fee Schedule Modernization Act of 2009 Reimbursement /Payment laboratory tests H.R. 676, US National Health Care Act or the Expanded and Improved Medicare for All Act S. 1110, Medicare Payment Advisory Commission Reform Act of 2009 H.R. 2502, Comparative Effectiveness Research Act of 2009 S. 1213, Patient Centered Outcomes Research Act of 2009 H.R. 3200, America's Affordable Health Choices Act of 2009 Reimbursement for Clinical Lab Tests Reimbursement for Medicare Part D Drugs S. 1679, America's Affordable Health Choices Act of 2009 H.R. 3962, Affordable Health Care for Americans Act H.R. 3590, Patient Protection & Affordable Health Care Act H.R. 4872, Health Care and Education Reconciliation Act of 2010 H.R. 4851, Continuing Extension Act of 2010 H.R. 4213, Workers, State, and Business Relief Act of 2010 H.R. 2847, Hiring Incentives to Restore Employment Act Extension of the TC Grandfather Clause
H.R. 1452, Medicare Clinical Diagnostic laboratory Fee Schedule Modernization Act of 2009 Reimbursement for clinical lab services under Medicare Excise Tax for laboratory services H.R. 3200, America's Affordable Health Choices Act of 2009 H.R. 3962, Affordable Health Care for Americans Act H.R. 3590, Patient Protection & Affordable Health Care Act
H.R. 4872, Health Care and Education Reconciliation Act of 2010
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 1452, Medicare Clinical Diagnostic laboratory Fee Schedule Modernization Act of 2009 Reimbursement for clinical lab services under Medicare Excise Tax for laboratory services Senate Finance Health Reform Bill H.R. 3200, America's Affordable Health Choices Act of 2009 House Tri-Committee Health Reform Bill H.R. 3962, Affordable Health Care for Americans Act H.R. 3590, Patient Protection & Affordable Health Care Act
S. 515, Patent Reform Act of 2009 H.R. 1260, Patent Reform Act of 2009 H.R. 1548, Pathway for Biosimilars Act of 2009 H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act, Follow-on Biologics S. 726, Promoting Innovation and Access to Life-Saving Medicines Act, Follow-on Biologics S. 610, Patent Reform Act of 2009 House Tri-Committee Health Reform Bill H.R. 3200 America's Affordable Health Choices Act of 2009 S. 1679, America's Affordable Health Choices Act of 2009 H.R. 3962, Affordable Health Care for Americans Act H.R. 3590, Patient Protection & Affordable Health Care Act
H.R. 444, 340B Program Improvement and Integrity Act of 2009, 340B drug price expansion H.R. 1832, Medicare Prescription Drug Affordability Act of 2009 S. 266, Medicare Prescription Drug Gap Reduction Act of 2009 S. 301, Physician Payments Sunshine Act of 2009 ESRD "bundling issues" and ESRD drug reimbursement issues HCPCS coding decisions Reimbursement for Part B Drugs administered in hospital out patient departments, dialysis centers and physician officers Physicians fee schedule payment rates for lab tests Medicaid rebates Implementation of MIPPA H.R. 1699 Patient Access to Critical Lab Test H.R. 1452 Medicare Clinical Diagnostic Laboratory Fee Schedule Modernization Act of 2009 Reimbursement /Payment laboratory tests H.R. 676 - US National Health Care Act or the Expanded and Improved Medicare for All Act House Tri-Committee Health Reform Bill Senate Finance Health Reform Bill S. 1110, Medicare Payment Advisory Commission Reform Act of 2009 H.R. 2502, Comparative Effectiveness Research Act of 2009 S. 1213, Patient Centered Outcomes Research Act of 2009 H.R. 3200, America's Affordable Health Choices Act of 2009 Reimbursement for Clinical Lab Tests Reimbursement for Medicare Part D Drugs S. 1679, America's Affordable Health Choices Act of 2009 H.R. 3962, Affordable Health Care for Americans Act H.R. 3590, Patient Protection & Affordable Health Care Act
H.R. 1548, Pathway for Biosimilars Act of 2009 H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act S. 726 Promoting Innovation and Access to Life-Saving Medicines Act S. 301 Physician Payments Sunshine Act of 2009 H.R. 3156, Neglected Disease Tax Credit Bill H.R. 1298, Pharmaceutical Market Access & Drug Safety Act of 2009" - Importation. S.525, "Pharmaceutical Market Access & Drug Safety Act of 2009" - Importation H.R. 759, Food and Drug Administration Globalization Act of 2009 S. 1679, America's Affordable Health Choices Act of 2009 House Tri-Caucus Health Reform Bill H.R. 3962, Affordable Health Care for Americans Act H.R. 3590, Patient Protection & Affordable Health Care Act Treatment of Orphan Drugs Under 340B Expansion
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 1548, Pathway for Biosimilars Act of 2009 H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act S. 726 Promoting Innovation and Access to Life-Saving Medicines Act S. 301 Physician Payments Sunshine Act of 2009 H.R. 3156, Neglected Disease Tax Credit Bill Neglected Disease Issues Issues related to Drug Safety, Generic Biologics & Drug Approvals Importation. H.R. 1298, Pharmaceutical Market Access & Drug Safety Act of 2009" - Importation. S.525, "Pharmaceutical Market Access & Drug Safety Act of 2009" - Importation H.R. 759, Food and Drug Administration Globalization Act of 2009
S. 515, Patent Reform Act of 2009 H.R. 1260, Patent Reform Act of 2009 H.R. 1548, Pathway for Biosimilars Act of 2009 H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act, Follow-on Biologics S. 726, Promoting Innovation and Access to Life-Saving Medicines Act, Follow-on Biologics S. 610, Patent Reform Act of 2009 Senate Draft Bill Biologics Price Competition and Innovation Act Kennedy Health Reform Bill House Tri-Committee Health Reform Bill Senate Finance Health Reform Bill H.R. 3200 America's Affordable Health Choices Act of 2009
H.R. 1452, Medicare Clinical Diagnostic laboratory Fee Schedule Modernization Act of 2009 Reimbursement for clinical lab services under Medicare Excise Tax for laboratory services Senate Finance Health Reform Bill H.R. 3200, America's Affordable Health Choices Act of 2009 House Tri-Committee Health Reform Bill
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
S. 515, Patent Reform Act of 2009 H.R. 1260, Patent Reform Act of 2009 H.R. 1548, Pathway for Biosimilars Act of 2009 H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act, Follow-on Biologics S. 726, Promoting Innovation and Access to Life-Saving Medicines Act, Follow-on Biologics S. 610, Patent Reform Act of 2009 Senate Draft Bill Biologics Price Competition and Innovation Act Kennedy Health Reform Bill House Tri-Committee Health Reform Bill
H.R. 1452, Medicare Clinical Diagnostic laboratory Fee Schedule Modernization Act of 2009 Reimbursement for clinical lab services under Medicare
H.R. 1 American Recovery and Reinvestment Act of 2009 S. Con. Res. 13 H.R.. Con. Res. 85 S. 350 American Recovery and Reinvestment Act of 2009 FDA, Homeland Security Appropriations H.R. 2997, Agriculture (FDA) Appropriations H.R. 2892, Homeland Security Appropriations
H.R. 444, 340B Program Improvement and Integrity Act of 2009, 340B drug price expansion H.R. 1832, Medicare Prescription Drug Affordability Act of 2009 S. 266, Medicare Prescription Drug Gap Reduction Act of 2009 S. 301, Physician Payments Sunshine Act of 2009 Comparative Effectiveness ESRD "bundling issues" and ESRD drug reimbursement issues Medicare prescription drug benefit CPT Coding decisions and HCPCS coding decisions Reimbursement for Part B Drugs administered in hospital out patient departments, dialysis centers and physician officers Physicians fee schedule payment rates for lab tests Medicaid rebates MIPPA Technical Corrections H.R. 1699 Patient Access to Critical Lab Test H.R. 1452 Medicare Clinical Diagnostic Laboratory Fee Schedule Modernization Act of 2009 Reimbursement /Payment laboratory tests S. 275 Children's Health Insurance Program Reauthorization Act of 2009 H.R. 2 Children's Health Insurance Program Reauthorization Act of 2009 H.R. 676 - US National Health Care Act or the Expanded and Improved Medicare for All Act Least Costly Alternative (LCA) policy for viscosupplements Kennedy Health Reform Bill House Tri-Committee Health Reform Bill Senate Finance Health Reform Bill S. 1110, Medicare Payment Advisory Commission Reform Act of 2009 H.R. 2502, Comparative Effectiveness Research Act of 2009 S. 1213, Patient Centered Outcomes Research Act of 2009
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
S. 515, Patent Reform Act of 2009 HR. 1260, Patent Reform Act of 2009 HR. 1548 Pathway for Biosimilars Act of 2009 HR. 1427, Promoting Innovation and Access to Life-Saving Medicines Act, Follow-on Biologics S. 726, Promoting Innovation and Access to Life-Saving Medicines Act, Follow-on Biologics S. 610 Patent Reform Act of 2009 Senate draft bill Biologics Price Competition and Innovation Act
H.R. 444, 340B Program Improvement and Integrity Act of 2009, 340B drug price expansion H.R. 1832 Medicare Prescription Drug Affordability Act of 2009 S. 266 Medicare Prescription Drug Gap Reduction Act of 2009 S. 301, Physician Payments Sunshine Act of 2009 Comparative Effectiveness ESRD "bundling issues" and ESRD drug reimbursement issues Medicare prescription drug benefit CPT Coding decisions and HCPCS coding decisions Reimbursement for Part B Drugs administered in hospital out patient departments, dialysis centers and physician officers Physicians fee schedule payment rates for lab tests. Medicaid rebates MIPPA Technical Corrections H.R. 1699 Patient Access to Critical Lab Test H.R. 1452 Medicare Clinical Diagnostic Laboratory Fee Schedule Modernization Act of 2009 Reimbursement /Payment laboratory tests S. 275 Children's Health Insurance Program Reauthorization Act of 2009 H.R. 2 Children's Health Insurance Program Reauthorization Act of 2009 H.R. 676 - US National Health Care Act or the Expanded and Improved Medicare for All Act Least Costly Alternative (LCA) policy for viscosupplements
H.R. 1548, Pathway for Biosimalars Act of 2009 H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act S. 726 Promoting Innovation and Access to Life-Saving Medicines Act S. 301 Physician Payments Sunshine Act of 2009 Neglected Disease Issues Issues related to Drug Safety, Generic Biologics & Drug Approvals Importation. H.R. 1298, Pharmaceutical Market Access & Drug Safety Act of 2009" - Importation. S.525, "Pharmaceutical Market Access & Drug Safety Act of 2009" - Importation H.R. 759 Food and Drug Administration Globalization Act of 2009
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S. 1145, Patent Reform Act of 2007 HR. 1908, Patent Reform Act of 2007 HR. 1038, Access to Life-Saving Medicine Act, Follow-on Biologics HR. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, Follow-on Biologics HR. 5629, Pathway for Biosimilars Act S. 1505, Affordable Biologic for Consumers Act of 2007, follow-on Biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on Biologics S. 623, Access to Life-Saving Medicine Act, Follow-on biologics S. 3600 Patent Reform Act of 2008
H.R. 1424, Emergency Economic Stabilization Act of 2008 Neglected Disease Tax Credit
H.R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, Follow-on biologics H.R. 5629, Pathway for Biosimilars Act S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S.1695, Biologics Price Competition and Innovation Act of 2007, Follow-on Biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 623, Access to Life-Saving Medicine Act, follow-on biologics Neglected Disease Issues Issues related to Drug Safety, Generic Biologics & Drug Approvals H.R. 380, "Pharmaceutical Market Access and Drug Safety Act of 2007" - Importation. S.251, Pharmaceutical Market Access & Drug Safety Act of 2007" - Importation. S.242, "Pharmaceutical Market Access & Drug Safety Act of 2007" H.R. 1561, Enhancing Drug Safety and Innovation Act of 2007 H.R. 3610 Food and Drug Import Safety Act of 2007 S. 4, Improving America's Security Act of 2007, cargo-screening provision
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S. 1145, Patent Reform Act of 2007 HR. 1908, Patent Reform Act of 2007 HR. 1038, Access to Life-Saving Medicine Act, Follow-on Biologics HR. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, Follow-on Biologics HR. 5629, Pathway for Biosimilars Act S. 1505, Affordable Biologic for Consumers Act of 2007, follow-on Biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on Biologics S. 623, Access to Life-Saving Medicine Act, Follow-on biologics S. 3600 Patent Reform Act of 2008
H.R. 1424, Emergency Economic Stabilization Act of 2008 Neglected Disease Tax Credit
H.R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, Follow-on biologics H.R. 5629, Pathway for Biosimilars Act S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S.1695, Biologics Price Competition and Innovation Act of 2007, Follow-on Biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 623, Access to Life-Saving Medicine Act, follow-on biologics Neglected Disease Issues Issues related to Drug Safety, Generic Biologics & Drug Approvals H.R. 380, "Pharmaceutical Market Access and Drug Safety Act of 2007" - Importation. S.251, Pharmaceutical Market Access & Drug Safety Act of 2007" - Importation. S.242, "Pharmaceutical Market Access & Drug Safety Act of 2007" H.R. 1561, Enhancing Drug Safety and Innovation Act of 2007 H.R. 3610 Food and Drug Import Safety Act of 2007 S. 4, Improving America's Security Act of 2007, cargo-screening provision
H.R. 3453, Community Clinical Laboratory Fairness in Competition Act of 2007 Reimbursement for clinical lab services under Medicare H.R. 1321 "Medicare Advanced Laboratory Diagnostics Act"; S.2404 "The Medicare Advanced Laboratory Diagnostic Act of 2007" S.976 "Genomics & Personalized Medicine Act of 2007" Competitive bidding for lab tests S.736, "The Laboratory Test Improvement Act"
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 3453, Community Clinical Laboratory Fairness in Competition Act of 2007 Reimbursement for clinical lab services under Medicare H.R. 1321 "Medicare Advanced Laboratory Diagnostics Act"; S.2404 "The Medicare Advanced Laboratory Diagnostic Act of 2007" S.976 "Genomics & Personalized Medicine Act of 2007" Competitive bidding for lab tests S.736, "The Laboratory Test Improvement Act"
H.R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, Follow-on biologics H.R. 5629, Pathway for Biosimilars Act S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S.1695, Biologics Price Competition and Innovation Act of 2007, Follow-on Biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 623, Access to Life-Saving Medicine Act, follow-on biologics Neglected Disease Issues Issues related to Drug Safety, Generic Biologics & Drug Approvals H.R. 380, "Pharmaceutical Market Access and Drug Safety Act of 2007" - Importation. S.251, Pharmaceutical Market Access & Drug Safety Act of 2007" - Importation. S.242, "Pharmaceutical Market Access & Drug Safety Act of 2007" H.R. 1561, Enhancing Drug Safety and Innovation Act of 2007 H.R. 3610 Food and Drug Import Safety Act of 2007
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S. 1145, Patent Reform Act of 2007 HR. 1908, Patent Reform Act of 2007 H.R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics H.R. 5629, Pathway for Biosimilars Act S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, Follow-on Biologics S. 623, Access to Life-Saving Medicine Act, follow-on biologics
H.R. 2606, 340B Program Improvement and Integrity Act of 2007, 340 B drug price expansion H.R. 3162, Children's Health and Medicare Protection Act of 2007 H.R. 4, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provisions H.R. 5480, Medicare Funding Warning Response Act of 2008 S. 1376, 340B Program Improvement and Integrity Act of 2007, 340 B Drug price expansion S. 2029, Physician Payments Sunshine Act of 2007 S. 2662, Medicare Funding Warning Response Act of 2008 S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provision Comparative Effectiveness S. 2099 "Preserving Access to Laboratory Services Act of 2007" Repeal of competitive bidding demo Bundling payment system for dialysis centers Medicare prescription drug benefit H.R. 1321 "Medicare Advanced Laboratory Diagnostics Act of 2007" S.2404 "The Medicare Advanced Laboratory Diagnostic Act of 2007" S.691/H.R. 1193 The Kidney Care Quality and Education Act CPT Coding decisions and HCPCS coding decisions Reimbursement for Part B Drugs administered in hospital outpatient departments, dialysis centers and physician officers. Physicians fee schedule payment rates for lab tests. Medicaid rebates H.R. 2184, the Enhanced Health Care Value for All Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
a) Issues related to Drug Safety, Generic Biologics & Drug Approvals, FDA User Fees. b) S.1082, "Food & Drug Administration Revitalization Act of 2007" c) H.R. 2900, Food & Drug Administrtion Amendments Act of 2007" d) H.R. 380, "Pharmaceutical Market Access and Drug Safety act of 2007" - Importation.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
e) Senate Concurrent Resolution 21 f) S.251, Pharmaceutical Market Access & Drug Safety Act of 2007" - Importation. g) S. 242, "Pharmaceutical Market Access & Drug Safety Act of 2007" a) Issues related to Drug Safety, Generic Biologics & Drug Approvals, FDA User Fees. b) S.1082, "Food & Drug Administration Revitalization Act of 2007" c) H.R. 2900, "Food & Drug Administration Amendments Act of 2007" d) H.R. 380, "Pharmaceutical Market Access and Drug Safety Act of 2007" - Importation.
d) S.691/H.R. 1193 The Kidney Care Quality and Education Act e) H.R. 3162, The Children's Health and Medicare Protection Act of 2007 f) CPT Coding decisions g) Reimbursement for Part B Drugs administered in hospital outpatient departments, dialysis centers and physician officers. h) Implementation of the Competitive Acquisition (CAP) Program for Part B Drugs. i) 340B Programs. j) CMS guidance on coverage under evidence development. k) Physicians fee schedule payment rates for lab tests. l) Medicaid budget reductions. m) Medicaid rebates n) H.R. 2184, the Enhanced Health Care Value for All Act o) Technology assessment report on osteoarthritis treatments a) Medicare Prescription Drug Benefit: Implementation of issues associated w/P.L. 108-173, including reimbursement for orphan drugs. b) H.R. 1321 “Medicare Advanced Laboratory Diagnostics Act of 2007”, reimbursement for lab tests c) Bundling Payment system for dialysis centers
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE
e) S. 109, "Pharmaceutical Market Access Act of 2005". f) S. 334, "Pharmaceutical Market Access & Drug Safety Act of 2005". g) Issues related to clinical trial data bank. h) S. 470, H.R. 3196, "Fair Access to Clinical Trials Act". i) H.R. 6257, "Access to Life-Saving Medicines Act". a) Issues related to Drug Safety, Generic Biologics & Drug Approvals, FDA User Fees. b) S.930, "Food & Drug Administration Act of 2005". c) H.R. 2090, "Food & Drug Administration Improvement Act of 2005". d) H.R. 700, "Pharmaceutical Market Access & Drug Safety Act of 2005" - Importation.
a) Regulatory framework affecting generic biologics. b) Patent reform issues. c) H.R. 2795, "The Patent Reform Act of 2005". d) Process patents.
a) Reimbursement for clinical lab services under Medicare. b) H.R. 5369, "Advanced Laboratory Diagnostics Act of 2006". c) S. 3822, "Genomics & Personalized Medicine Act of 2006". d) H.R. 6408, "Tax Relief and Health Care Act of 2006".
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
a) Regulatory framework affecting generic biologics. b) Patent reform issues. c) H.R. 2795, "The Patent Reform Act of 2005". d) Process patents.
a) Reimbursement for clinical lab services under Medicare. b) H.R. 5369, "Advanced Laboratory Diagnostics Act of 2006". c) S. 3822, "Genomics & Personalized Medicine Act of 2006". d) H.R. 6408, "Tax Relief and Health Care Act of 2006".
c) Reimbursement for Part B Drugs administered in hospital outpatient departments, dialysis centers and physician offices. d) Implementation of the Competitive Acquisition (CAP) Program for Part B Drugs. e) 340B Programs. f) H.R. 4241, "Deficit Reduction Act of 2005". g) S. 1932, "Deficit Reduction Omnibus Reconciliation Act of 2005". h) CMS guidance on coverage under evidence development. i) Physicians fee schedule payment rates for lab tests. j) Medicaid budget reductions. k) H.R. 6408, "Tax Relief and Health Care Act of 2006". l) Medicaid rebates a) Medicare Prescription Drug Benefit: Implementation of issues associated w/P.L. 108-173, including reimbursement for orphan drugs. b) HCPCS Workgroup Coding Decisions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office